← FDA DRUG APPROVALS

FDA ANDA · ANDA077807

BALSALAZIDE DISODIUM

Sponsor: NOVITIUM PHARMA

APPLICATION
ANDA077807
TYPE
ANDA
ORIGINAL APPROVAL
2007-12-28
LATEST ACTION
2025-06-23
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

BALSALAZIDE DISODIUMPrescription
BALSALAZIDE DISODIUM 750MG · CAPSULE · ORAL

Approval history

2025-06-23Labeling · Supplement 8 · standardAP
2025-06-23Labeling · Supplement 6 · standardAP
2014-01-23Labeling · Supplement 4 · standardAP
2007-12-28OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →